NASDAQ:ALECAlector Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alector Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.43 +1.53 (+6.99 %) (As of 04/7/2020 02:53 AM ET) Add Compare Share Today's Range$22.48Now: $23.43▼$23.9850-Day Range$21.09MA: $26.64▼$31.3452-Week Range$13.64Now: $23.43▼$35.93Volume437,526 shsAverage Volume654,433 shsMarket Capitalization$1.84 billionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Alector has a potential upside of 19.5% from its current price of $23.43.Amount of Analyst CoverageAlector has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAlector has received 110 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlector has received 111 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlector has received 50.23% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote “Outperform” if you believe ALEC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold 3,288.89% more of their company's stock than they have bought. Specifically, they have bought $563,800.00 in company stock and sold $19,106,541.00 in company stock.Percentage Held by InsidersOnly 13.90% of the stock of Alector is held by insiders.Percentage Held by Institutions53.54% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to grow by 20.11% in the coming year, from ($1.79) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -13.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC Previous Symbol CUSIPN/A CIKN/A Webhttp://www.alector.com/ Phone415-231-5660Debt Debt-to-Equity Ratio0.21 Current Ratio5.77 Quick Ratio5.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.22 million Price / Sales86.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.83 per share Price / Book8.28Profitability EPS (Most Recent Fiscal Year)($1.71) Net Income$-105,390,000.00 Net Margins-496.65% Return on Equity-45.56% Return on Assets-22.85%Miscellaneous Employees91 Outstanding Shares78,525,000Market Cap$1.84 billion Next Earnings Date5/11/2020 (Estimated) OptionableNot Optionable Receive ALEC News and Ratings via Email Sign-up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALEC Rates by TradingView Alector (NASDAQ:ALEC) Frequently Asked Questions How has Alector's stock been impacted by COVID-19 (Coronavirus)? Alector's stock was trading at $24.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALEC shares have decreased by 6.0% and is now trading at $23.43. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Alector? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alector. When is Alector's next earnings date? Alector is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Alector. How were Alector's earnings last quarter? Alector Inc (NASDAQ:ALEC) announced its earnings results on Tuesday, March, 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.03. The company earned $6 million during the quarter, compared to analysts' expectations of $9.60 million. Alector had a negative net margin of 496.65% and a negative return on equity of 45.56%. View Alector's earnings history. What price target have analysts set for ALEC? 5 Wall Street analysts have issued 1 year price targets for Alector's stock. Their forecasts range from $28.00 to $28.00. On average, they expect Alector's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts' price targets for Alector. Has Alector been receiving favorable news coverage? Headlines about ALEC stock have trended very negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alector earned a news impact score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAlector. Who are some of Alector's key competitors? Some companies that are related to Alector include BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), bluebird bio (BLUE), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO). What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Cisco Systems (CSCO), Alibaba Group (BABA), Advanced Micro Devices (AMD), AT&T (T), Verizon Communications (VZ), Johnson & Johnson (JNJ), Pfizer (PFE) and Gossamer Bio (GOSS). Who are Alector's key executives? Alector's management team includes the following people: Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)Dr. Robert S. King, Chief Devel. Officer (Age 56)Dr. Asa Abeliovich M.D., Ph.D., Co-Founder When did Alector IPO? (ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. What is Alector's stock symbol? Alector trades on the NASDAQ under the ticker symbol "ALEC." How do I buy shares of Alector? Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alector's stock price today? One share of ALEC stock can currently be purchased for approximately $23.43. How big of a company is Alector? Alector has a market capitalization of $1.84 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe. View additional information about Alector. What is Alector's official website? The official website for Alector is http://www.alector.com/. How can I contact Alector? Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Hedge Funds - Risk or Reward?
